LDOC1L Antibody

What is LDOC1L and how does it relate to the LDOC1 family?

LDOC1L (Leucine zipper down-regulated in cancer 1-like) is a member of the LDOC1 family. It is a nuclear protein containing a leucine zipper-like motif similar to LDOC1, which is known to be down-regulated in various cancer cell lines. LDOC1L is encoded by the human gene with ID 84247 .

The protein is 263 amino acids in length (with research focusing on positions 1-239) and has a molecular mass of approximately 28.7 kDa as a recombinant protein . When detected in cellular systems, LDOC1L typically appears at 24-26 kDa in Western blot experiments, although this can vary depending on post-translational modifications .

While LDOC1 has been extensively studied as a tumor suppressor gene down-regulated in multiple cancers including pancreatic, gastric, and cervical cancer cell lines , LDOC1L remains less characterized but shares structural similarities suggesting potential related functions.

What are the key structural features of LDOC1L protein?

LDOC1L protein contains several important structural domains that contribute to its function:

• A leucine zipper-like motif, which typically mediates protein-protein interactions and DNA binding

• Sequence similarity to its family member LDOC1, which contains a proline-rich region that shares marked similarity with an SH3-binding domain

• Multiple potential phosphorylation sites, particularly at serine residues S17, S37, and S128, which suggest regulation via post-translational modifications

• A probable nuclear localization sequence, as the protein is predominantly found in the nucleus, similar to other family members

These structural features provide important insights into potential protein interactions and regulatory mechanisms that may be relevant to experimental design when using LDOC1L antibodies.

What applications are LDOC1L antibodies validated for?

Based on the available data, LDOC1L antibodies have been validated for the following applications:

When designing experiments, it is critical to select antibodies specifically validated for your intended application. Most commercial LDOC1L antibodies are polyclonal rabbit antibodies that recognize internal epitopes of the protein and show reactivity with human and mouse samples .

How should researchers optimize Western blot protocols for LDOC1L detection?

For optimal detection of LDOC1L via Western blot, researchers should consider the following methodological approach:

• Sample preparation:

  • Use standard cell lysis buffers containing protease inhibitors

  • Include phosphatase inhibitors if investigating phosphorylated forms

  • Prepare fresh samples when possible, as LDOC1L stability during long-term storage has not been well-characterized

• Gel selection and transfer:

  • Use 10-12% SDS-PAGE gels for optimal separation around the 24-26 kDa range

  • Consider gradient gels (4-20%) if investigating potential post-translational modifications

  • Use PVDF membranes for better protein retention and signal strength

• Antibody incubation:

  • Start with a 1:500 dilution for initial optimization

  • Incubate primary antibody overnight at 4°C for improved sensitivity

  • Use 5% BSA in TBST rather than milk for blocking and antibody dilution if phosphorylated forms are of interest

• Expected results:

  • The main band should appear at approximately 24-26 kDa

  • Secondary bands may appear due to post-translational modifications

  • Validate specificity using positive controls such as HeLa or SKOV-3 cells, which have been confirmed to express detectable levels of LDOC1L

This protocol can be adjusted based on specific experimental needs and antibody manufacturer recommendations.

What are the key considerations for immunofluorescence experiments with LDOC1L antibodies?

When performing immunofluorescence experiments with LDOC1L antibodies, researchers should consider:

• Fixation method:

  • 4% paraformaldehyde (10-15 minutes at room temperature) preserves protein structure while maintaining cellular architecture

  • Methanol fixation may be preferred if examining nuclear localization

  • Avoid harsh fixatives that might destroy the epitope recognized by your antibody

• Permeabilization:

  • Use 0.1-0.2% Triton X-100 for nuclear protein access

  • Extend permeabilization time (10-15 minutes) to ensure nuclear access

• Antibody incubation:

  • Optimize dilution through titration experiments

  • Extend primary antibody incubation to overnight at 4°C

  • Include a nuclear counterstain (such as DAPI) to confirm nuclear localization

• Controls:

  • Include secondary-only controls to assess non-specific binding

  • Use cells with confirmed LDOC1L expression (e.g., HeLa cells) as positive controls

  • Consider including cells treated with LDOC1L siRNA as negative controls

• Interpretation:

  • LDOC1L is expected to show primarily nuclear localization

  • Compare patterns with those of related proteins like LDOC1

  • Document subcellular distribution carefully, as this information is limited in the current literature

How can researchers verify the specificity of LDOC1L antibodies?

Verifying antibody specificity is crucial for reliable research results. For LDOC1L antibodies, consider these validation approaches:

• Genetic approaches:

  • Knockdown experiments using siRNA or shRNA against LDOC1L

  • CRISPR-Cas9 knockout of LDOC1L

  • Overexpression of tagged LDOC1L to compare with endogenous staining patterns

• Peptide competition assays:

  • Pre-incubate the antibody with excess immunizing peptide

  • The specific signal should be significantly reduced or eliminated

  • Non-specific signals will remain unchanged

• Cross-reactivity assessment:

  • Test the antibody in species or cell types not expected to express LDOC1L

  • Examine related family members (like LDOC1) to ensure specificity

  • Verify reactivity in multiple cell lines with known expression patterns

• Multiple antibody comparison:

  • Use antibodies from different manufacturers that target different epitopes

  • Consistent results across different antibodies increase confidence in specificity

  • Discrepancies may highlight isoform-specific detection or non-specific binding

• Mass spectrometry validation:

  • Immunoprecipitate with the LDOC1L antibody and verify the pulled-down protein by mass spectrometry

  • This provides the highest level of validation for antibody specificity

Documenting these validation steps is essential for publication and reproducibility of research findings.

How does LDOC1L function in relation to the NF-κB pathway, and how can researchers investigate this relationship?

While direct evidence for LDOC1L's role in the NF-κB pathway is limited, research on the related LDOC1 protein provides important insights that may guide LDOC1L research:

LDOC1 has been shown to be a negative regulator of NF-κB signaling . To investigate whether LDOC1L plays a similar role, researchers could:

• Establish baseline regulation:

  • Perform co-immunoprecipitation experiments to determine if LDOC1L interacts with NF-κB pathway components

  • Use NF-κB reporter assays following LDOC1L overexpression or knockdown

  • Compare findings with LDOC1's known interactions to identify similarities and differences

• Mechanistic investigations:

  • Examine if LDOC1L affects p65 protein stability or phosphorylation state

  • Investigate nuclear translocation of NF-κB subunits in the presence/absence of LDOC1L

  • Determine if LDOC1L affects IκB degradation in response to stimuli

• Functional validation:

  • Monitor expression of NF-κB target genes following LDOC1L manipulation

  • Investigate if LDOC1L affects cell proliferation and apoptosis similar to LDOC1

  • Determine if LDOC1L's effects are cell-type specific

• Experimental approach:

  • Treat cells with NF-κB activators (TNF-α, IL-1β) and examine LDOC1L expression

  • Create deletion mutants to map domains responsible for any observed effects

  • Use proximity ligation assays to detect in situ protein interactions

This systematic approach would help determine if LDOC1L functions similarly to LDOC1 in the NF-κB pathway or has distinct regulatory roles.

What is known about LDOC1L expression in cancer, and how can researchers further investigate its potential role as a biomarker?

While LDOC1 has been extensively studied as a tumor suppressor gene down-regulated in multiple cancers , less is known specifically about LDOC1L in cancer contexts. To investigate LDOC1L as a potential cancer biomarker:

Based on research with LDOC1, which showed tumor suppressor activities in hepatocellular carcinoma by inhibiting the AKT/mTOR pathway , similar investigations with LDOC1L could reveal whether it shares these properties or has distinct roles in tumor biology.

How can researchers investigate potential splice variants of LDOC1L and their functional significance?

Research on LDOC1 has identified splice variants (such as LDOC1S) that may have distinct functions. To investigate LDOC1L splice variants:

• Identification approach:

  • Analyze RNA-seq data from diverse tissue types to identify potential splice variants

  • Perform RT-PCR with primers spanning exon junctions

  • Use 5' and 3' RACE to identify alternative transcription start sites and polyadenylation sites

• Variant-specific detection:

  • Design PCR primers specific to each variant

  • Develop variant-specific antibodies or epitope tags for protein detection

  • Create a reference standard for each variant to enable quantification

• Tissue and condition-specific expression:

  • Profile variant expression across normal and disease tissues

  • Investigate regulation under different cellular stresses

  • Examine developmental and cell-cycle dependent expression

• Functional characterization:

  • Express individual variants in cellular models

  • Compare subcellular localization of different variants

  • Assess functional readouts (protein interactions, signaling pathway effects)

• Methodological approach for splice variant discrimination:

  • Design TaqMan probe and primer sets that distinguish between variants

  • Perform template specificity assays to confirm discrimination capacity

  • Use synthetic templates of predicted splice variants as controls

Based on the LDOC1 research, which used specific TaqMan probe and primer sets to distinguish between LDOC1 and LDOC1S with high specificity (14 × 10^6-fold specificity) , a similar approach could be applied to investigate potential LDOC1L splice variants.

What are the common challenges when working with LDOC1L antibodies and how can they be addressed?

Researchers working with LDOC1L antibodies may encounter several challenges:

• Low signal intensity:

  • Solution: Try increased antibody concentration (1:500 instead of 1:1000)

  • Solution: Extended incubation times (overnight at 4°C)

  • Solution: Enhanced detection systems (amplified chemiluminescence)

  • Solution: Concentrate protein samples or use immunoprecipitation to enrich

• Multiple bands on Western blot:

  • Solution: Verify expected molecular weight (24-26 kDa)

  • Solution: Use positive control lysates (HeLa, SKOV-3 cells)

  • Solution: Perform peptide competition assay to identify specific bands

  • Solution: Consider post-translational modifications like phosphorylation at S17, S37, S128 sites

• High background:

  • Solution: Increase blocking time and washing steps

  • Solution: Try different blocking agents (BSA vs. milk)

  • Solution: Use more stringent washing conditions

  • Solution: Reduce secondary antibody concentration

• Inconsistent results between experiments:

  • Solution: Standardize lysate preparation protocols

  • Solution: Aliquot antibodies to avoid freeze-thaw cycles

  • Solution: Include consistent positive controls

  • Solution: Measure total protein loading using methods like Ponceau S staining

• Cross-reactivity concerns:

  • Solution: Validate with genetic approaches (siRNA knockdown)

  • Solution: Compare results with antibodies from different manufacturers

  • Solution: Use recombinant LDOC1L protein as a positive control

  • Solution: Consider potential cross-reactivity with LDOC1 (the related family member)

When publishing results with LDOC1L antibodies, thoroughly document troubleshooting steps and validation approaches to enhance reproducibility.

How can researchers optimize co-immunoprecipitation protocols to study LDOC1L protein interactions?

To study LDOC1L protein interactions through co-immunoprecipitation (co-IP), consider these methodological optimizations:

• Lysis buffer optimization:

  • Use mild NP-40 or Triton X-100 based buffers (0.5-1%) to preserve protein-protein interactions

  • Include protease and phosphatase inhibitors

  • Adjust salt concentration (150-300 mM) to balance specificity with interaction preservation

  • Consider adding protein stabilizers like glycerol (10%) for nuclear proteins

• Antibody selection and validation:

  • Verify the antibody can recognize native (non-denatured) LDOC1L

  • Test both N-terminal and C-terminal targeting antibodies

  • Consider epitope-tagged LDOC1L constructs if antibody performance is suboptimal

  • Validate IP efficiency using Western blot of input, unbound, and IP fractions

• IP protocol optimization:

  • Pre-clear lysates with protein A/G beads to reduce non-specific binding

  • Test different antibody-to-lysate ratios

  • Compare direct antibody coupling to beads vs. antibody-then-beads approach

  • Optimize incubation times (4-16 hours at 4°C)

• Washing conditions:

  • Begin with manufacturer-recommended conditions

  • Adjust stringency based on signal-to-noise ratio

  • Consider detergent concentration and salt gradient washes

  • Maintain consistent temperature (4°C) throughout

• Controls to include:

  • IgG control from same species as LDOC1L antibody

  • Input sample (5-10% of lysate used for IP)

  • Lysate from cells with LDOC1L knockdown

  • Reverse co-IP with antibodies against suspected interacting partners

• Detection approach:

  • Western blot for suspected interacting partners

  • Mass spectrometry for unbiased discovery of interactions

  • Proximity ligation assay for in situ validation

Based on studies with LDOC1, which successfully demonstrated interaction with GNL3L through co-immunoprecipitation , similar approaches can be applied to investigate LDOC1L interactions.

What are the best practices for quantifying LDOC1L expression levels in tissue samples?

For accurate quantification of LDOC1L expression in tissue samples, researchers should consider:

• RNA-based quantification (RT-qPCR):

  • Design primers spanning exon-exon junctions to avoid genomic DNA amplification

  • Validate primer efficiency using standard curves

  • Use multiple reference genes for normalization (GAPDH, β-actin, 18S rRNA)

  • Consider potential splice variants when designing primers and interpreting results

  • Include positive controls (tissues/cells with known LDOC1L expression)

• Protein-based quantification (Western blot):

  • Use total protein normalization methods (Ponceau S, REVERT total protein stain)

  • Include a concentration curve of recombinant LDOC1L for absolute quantification

  • Apply consistent image acquisition settings between samples

  • Use digital image analysis software for densitometry

  • Report results as fold-change relative to appropriate controls

• Immunohistochemistry quantification:

  • Standardize tissue processing and staining protocols

  • Use automated staining platforms when possible to reduce variability

  • Employ digital pathology approaches for objective quantification

  • Define scoring systems (H-score, Allred score) appropriate for nuclear proteins

  • Include pathologist blind assessment for validation

• Considerations for specific tissue types:

  • Account for tissue heterogeneity in tumor samples

  • Use laser capture microdissection for specific cell populations if needed

  • Apply tissue-specific protein extraction protocols

  • Consider fixation effects on epitope accessibility

• Validation across methods:

  • Correlate mRNA and protein expression data

  • Compare results across multiple antibodies when possible

  • Validate IHC findings with Western blot when feasible

These approaches have been successfully applied in studies of LDOC1 expression in hepatocellular carcinoma and chronic lymphocytic leukemia , and can be adapted for LDOC1L expression studies.

How might LDOC1L's interaction with signaling pathways impact cancer research?

Based on knowledge of the related LDOC1 protein, several key research directions for LDOC1L in cancer signaling include:

• NF-κB pathway regulation:

  • LDOC1 is a known negative regulator of NF-κB

  • Research should investigate if LDOC1L similarly affects NF-κB activity

  • This could impact understanding of inflammation-driven cancers

  • Approach: Compare effects of LDOC1L vs. LDOC1 on NF-κB reporter activity in various cancer cell lines

• AKT/mTOR pathway modulation:

  • LDOC1 has been shown to inhibit AKT/mTOR activation in hepatocellular carcinoma

  • Researchers should examine if LDOC1L affects phosphorylation of AKT and mTOR

  • This pathway is critical in cellular growth, proliferation, and metabolism

  • Approach: Western blot analysis of phosphorylated vs. total AKT and mTOR in cells with LDOC1L overexpression or knockdown

• Pro-apoptotic functions:

  • LDOC1 expression increases apoptotic cell populations

  • LDOC1L should be investigated for similar effects

  • Approach: Flow cytometry with Annexin-V staining in cells with modulated LDOC1L expression

• Cell proliferation impact:

  • Research indicates LDOC1 inhibits cell growth

  • LDOC1L's effects on proliferation markers should be examined

  • Approach: MTT/XTT assays, BrdU incorporation, and cell cycle analysis following LDOC1L manipulation

• Protein destabilization mechanisms:

  • LDOC1 promotes GNL3L protein destabilization

  • LDOC1L may have similar effects on interacting proteins

  • Approach: Cycloheximide chase assays with potential LDOC1L-interacting proteins

Understanding these interactions could identify LDOC1L as a potential therapeutic target or prognostic marker in specific cancer types, similar to how LDOC1 has emerged as a favorable prognostic biomarker in hepatocellular carcinoma .

What are the key considerations for developing new and improved LDOC1L research tools?

To advance LDOC1L research, development of improved research tools should focus on:

• Next-generation antibodies:

  • Develop monoclonal antibodies with defined epitopes

  • Create isoform-specific antibodies if splice variants are identified

  • Produce phospho-specific antibodies targeting known phosphorylation sites (S17, S37, S128)

  • Validate across multiple applications (WB, IP, IF, IHC, ChIP)

• Recombinant proteins and peptides:

  • Produce full-length and domain-specific recombinant LDOC1L

  • Develop tagged versions (His, GST, FLAG) for pull-down experiments

  • Create peptide arrays for domain-specific interaction mapping

  • Generate phosphorylated and non-phosphorylated peptide standards

• Genetic tools:

  • Design validated siRNA/shRNA constructs with minimal off-target effects

  • Develop CRISPR-Cas9 knockout and knock-in systems

  • Create inducible expression systems for temporal control

  • Generate fluorescently tagged constructs for live-cell imaging

• Cellular and animal models:

  • Establish cell lines with stable LDOC1L overexpression or knockout

  • Develop transgenic mouse models with tissue-specific expression

  • Create patient-derived xenografts with varying LDOC1L expression levels

  • Design reporter cell lines for LDOC1L pathway activation

• High-throughput screening approaches:

  • Develop assays suitable for compound library screening

  • Create biosensors for real-time monitoring of LDOC1L interactions

  • Establish proteomics workflows optimized for LDOC1L complexes

  • Design computational approaches to predict LDOC1L interactions

These improved tools would enable more rigorous investigation of LDOC1L's functions and potential role in disease processes, following the research trajectory seen with the better-characterized LDOC1 protein.

How can researchers best approach investigating the evolutionary conservation and divergence between LDOC1 and LDOC1L?

To understand the evolutionary relationship between LDOC1 and LDOC1L, researchers should consider:

• Comparative sequence analysis:

  • Perform phylogenetic analysis across species to determine evolutionary origin

  • Compare conserved domains between LDOC1 and LDOC1L

  • Analyze conservation of key functional regions (leucine zipper, proline-rich regions)

  • Identify species-specific variations that might indicate functional adaptation

• Structural biology approaches:

  • Determine tertiary structure through X-ray crystallography or cryo-EM

  • Compare structural features between LDOC1 and LDOC1L

  • Identify conserved binding interfaces

  • Model interactions with known partners

• Functional conservation testing:

  • Perform cross-species complementation experiments

  • Test if LDOC1L can rescue LDOC1 knockout phenotypes

  • Compare interaction partners between the two proteins

  • Examine tissue expression patterns across species

• Methodological approaches:

  • Use BLAST and multiple sequence alignment tools

  • Apply molecular modeling software

  • Employ biochemical approaches to test predicted functional equivalence

  • Use genetic engineering to create chimeric proteins

• Evolutionary context analysis:

  • Examine gene duplication events in vertebrate evolution

  • Analyze synteny around LDOC1 and LDOC1L loci

  • Compare promoter elements for insights into expression regulation

  • Investigate selective pressures through dN/dS ratios

This evolutionary perspective would provide valuable context for understanding the potential functional overlap and divergence between LDOC1 and LDOC1L, which could inform experimental design and interpretation of results.